Myometrial steroid concentration and oxytocin receptor density in parturient women at term.
The aim of this study was to measure oxytocin receptor concentration in myometrial tissue from term pregnant women with normal and dysfunctional labor and to relate this concentration to the progress of labor and to the levels of estradiol and progesterone in the same myometrium. Myometrial biopsies were obtained from 50 term pregnant women undergoing cesarean section. The patients were categorized as follows: not in labor, normal labor, successful oxytocin-augmented labor, and oxytocin-resistant labor. Specific binding of [3H]oxytocin to high-affinity sites in membrane preparations from myometrial tissues was determined. Estradiol and progesterone were assayed using tritiated steroids with a sensitive radioimmunoassay technique. Oxytocin receptor density was significantly lower in oxytocin-resistant labor compared to successful oxytocin-augmentated labor (P < 0.04) and to spontaneously active normal labor (P < 0.02). Oxytocin receptor concentration was also significantly lower in non-labor patients compared to normal spontaneous labor (P < 0.01), and successful oxytocin-augmented labor (P < 0.02). There was a positive relationship between the progress of cervical dilatation (cm/h) and oxytocin receptor density in the myometrium (r = 0.408, P < 0.025). The concentration of progesterone and estradiol in the pregnant myometrium did not differ in patients with different types of labor or with the state of uterine contractile activity. Our results suggest that individual myometrial sensitivity is an important determinant of the response to administered oxytocin in humans. Furthermore, myometrial oxytocin receptor expression in vivo seems not be related to ovarian steroid concentration in the myometrium. The low oxytocin receptor density in oxytocin-resistant dystocia needs further investigation.
Rezapour
M
M
Department of Obstetrics and Gynecology, University of Uppsala, Sweden.
Bäckström
T
T
Ulmsten
U
U
D000328:Adult; D001665:Binding Sites; D002584:Cervix Uteri / Q000187:drug effects / Q000502:physiology; D002585:Cesarean Section; D004958:Estradiol / Q000378:metabolism*; D005260:Female; D006801:Humans; D007751:Labor, Induced; D007743:Labor, Obstetric / Q000187:drug effects / Q000378:metabolism*; D009215:Myometrium / Q000378:metabolism*; D010121:Oxytocin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D011374:Progesterone / Q000378:metabolism*; D018045:Receptors, Oxytocin / Q000378:metabolism*; D014590:Uterine Contraction / Q000187:drug effects / Q000378:metabolism
D018045:Receptors, Oxytocin; D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin